Regenexx® Announces Issue of United States Patent on Proprietary Orthopedic Stem Cell Procedure
DENVER, Oct. 28, 2015 /PRNewswire/ -- Regenexx® today announced the recent issue of a US Patent on their proprietary same day stem cell procedure used to treat joint injuries, spine pain and degenerative orthopedic conditions, such as osteoarthritis. This patent continues to add to the company's expanding intellectual (IP) property portfolio.
To review this patent, visit: https://www.google.com/patents/US8871199
US Patent 8871199 B2 focuses on the use of an inflammatory agent to prompt repair of cartilage by stem cells. "Consider this a patent on the use of a 'till the soil' injection before you plant the seeds (stem cells)," stated company CEO, Christopher Centeno, MD.
The new patent is key in protecting Regenexx intellectual property on their proprietary same-day stem cell procedure for orthopedic conditions. Regenexx has been clinically studying and publishing on this procedure for many years.
Regenexx has published approximately 33% of the world's peer-reviewed research on the use of stem cells for treating orthopedic conditions as of the date of this announcement. The company currently holds numerous patents, with additional patents in the review process.
About Regenexx
The Regenexx® Procedures are the nation's most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient's own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.
For more information on Regenexx, please visit: http://www.regenexx.com
Media Contact:
Mark Testa
(303) 885-9630
SOURCE Regenexx
DENVER, Oct. 28, 2015 /PRNewswire/ -- Regenexx® today announced the recent issue of a US Patent on their proprietary same day stem cell procedure used to treat joint injuries, spine pain and degenerative orthopedic conditions, such as osteoarthritis. This patent continues to add to the company's expanding intellectual (IP) property portfolio.
To review this patent, visit: https://www.google.com/patents/US8871199
US Patent 8871199 B2 focuses on the use of an inflammatory agent to prompt repair of cartilage by stem cells. "Consider this a patent on the use of a 'till the soil' injection before you plant the seeds (stem cells)," stated company CEO, Christopher Centeno, MD.
The new patent is key in protecting Regenexx intellectual property on their proprietary same-day stem cell procedure for orthopedic conditions. Regenexx has been clinically studying and publishing on this procedure for many years.
Regenexx has published approximately 33% of the world's peer-reviewed research on the use of stem cells for treating orthopedic conditions as of the date of this announcement. The company currently holds numerous patents, with additional patents in the review process.
About Regenexx
The Regenexx® Procedures are the nation's most advanced non-surgical stem cell and blood platelet treatments for common joint injuries and degenerative joint conditions, such as osteoarthritis and avascular necrosis. These stem cell procedures utilize a patient's own stem cells or blood platelets to help heal damaged tissues, tendons, ligaments, cartilage, spinal disc, or bone.
For more information on Regenexx, please visit: http://www.regenexx.com
Media Contact:
Mark Testa
(303) 885-9630
SOURCE Regenexx